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Recently, in this journal, Dr Undurti Das [1] suggested that
treatment of sepsis, septic shock and burns should also
include infusion of glucose–insulin–potassium (GIK), with the
objective of the infusion being to achieve plasma glucose
concentrations below 6.1 mmol/l (<110 mg/dl). That
conclusion was based on the combined results of a number
of studies. In our opinion, however, no single clinical trial has
yet been reported that supports this conclusion.
Euglycaemia in critically ill patients
It has been shown that achieving and maintaining
euglycaemia (i.e. plasma glucose concentrations of
4.4–6.1 mmol/l) in patients admitted to surgical intensive
care units leads to marked reductions in morbidity and
mortality [2]. However, in that study the investigators did not
use a GIK infusion; rather, meticulous regulation of serum
glucose was achieved by combining intensive insulin
treatment with intravenous glucose (200–300 g/24 hours).
The following day the infusion was replaced by parenteral
nutrition, combined parenteral and enteral nutrition, or enteral
nutrition, according to a set scheme. Potassium was only
supplemented when a check-up showed that hypokalaemia
was either imminent or present (G van den Berghe, ICC van
der Horst, personal correspondence).
Glucose–insulin–potassium infusion in
sepsis, septic shock and burns patients
No studies are available in cases of sepsis, septic shock and
burn patients in which euglycaemia was pursued with the aid
of GIK infusion and that assessed mortality. There are few
data pertaining to the haemodynamic effects of GIK in
sepsis. In 15 patients with septic shock, GIK infusion led to
an increase in cardiac output [3]. This effect was also shown
in 14 patients with peritonitis and signs of hypovolaemic
shock, in spite of positive fluid balance and cathecholamine
treatment [4]. In burns victims intravenous GIK had the same
effect [5]. This appears to clarify the roles of the individual
components of GIK, in particular with regard to
haemodynamic support of the patient by insulin [6]. In the
study conducted in a surgical intensive care unit [2], patients
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Abstract
There is no hard evidence yet for a positive effect of glucose–insulin–potassium infusion in sepsis,
septic shock or burn patients. Each individual element of the glucose–insulin–potassium regimen, and
eventually euglycaemia, should theoretically be beneficial. At present, evidence exists only for reduced
mortality with strict metabolic treatment (i.e. blood glucose levels of 4.4–6.1 mmol/l) in critically ill
patients admitted to surgical intensive care units, and for better metabolic regulation (i.e. blood glucose
levels of 7.0–10.0 mmol/l) in patients with hyperglycaemia and/or diabetes mellitus, and in patients
without signs of heart failure (i.e. Killip class I) during acute myocardial infarction.
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with sepsis formed a small subgroup (maximum 5%). The
fact that there were four times as many patients who died
from established sepsis in the conventionally treated group
as compared with the intensively treated group supports the
value of intervention in glucose metabolism during sepsis. A
problem that should be anticipated is obtaining and
maintaining euglycaemia; after all, one of the features of
sepsis is the presence of hyperglycaemia as well as
hypoglycaemia. The scheme used in the above-mentioned
study [2] has not been validated in septic patients. It is to be
expected that serum glucose values will have to be checked
more frequently than once every 2–4 hours.
Metabolic treatment in acute myocardial
infarction
Metabolic treatment during myocardial ischaemia has been
studied before. The Diabetes Insulin Glucose Infusion Acute
Myocardial Infarction (DIGAMI) study, which included 620
patients, is the only study that aimed at meticulous regulation
of serum glucose concentrations by infusing glucose and
insulin [7,8]. Patients with known diabetes mellitus or serum
glucose concentrations greater than 11.0 mmol/l were
randomly assigned to an insulin–glucose infusion for
24 hours, followed by a minimum of 3 months of intensive
insulin therapy, or to conventional treatment. The objective
was to maintain serum glucose concentrations between 7.0
and 10.0 mmol/l, which is well above concentration range of
4.4–6.1 mmol/l referred to above. After 1 year, those
investigators found that, in particular, the group of patients
who had had no previous insulin treatment and were not
known to have risk factors such as a history of myocardial
infarction gained most from the glucose metabolism
intervention (mortality was 8.6% versus 18.0% in the control
group). For the study population as a whole, the absolute
reduction in mortality was 7.5% (P = 0.0273).
However, a definite place for GIK infusion in the treatment of
acute myocardial infarction has not yet been settled. In 1997,
a meta-analysis of studies of GIK in the treatment of acute
myocardial infarction was published [9]. That meta-analysis
included nine studies and 1932 patients, and showed that
GIK treatment resulted in a reduction in 30-day mortality from
21% to 16.1% (P = 0.004). In the four studies in which GIK
was administered at high doses (n = 228) the difference
appeared to be even larger: a reduction from 12% to 6.5%
(not significant). There were substantial differences between
the nine studies, in particular with regard to the time at which
the first symptoms appeared and the start of treatment, and
regarding the composition of the GIK cocktail and the
duration of treatment. Moreover, only 17 patients were
treated by adding GIK to reperfusion, which is the present
standard treatment.
The Estudios Cardiologicos Latinoamerica (ECLA) pilot trial
[10], including 490 patients, showed that 30-day mortality in
the group of patients randomly assigned to GIK was lower
than that in the control group (6.7% versus 11.5%; not
significant). As mentioned in the commentary of Das [1], the
effect was most pronounced in patients in whom GIK had
been combined with reperfusion treatment, mostly
thrombolysis (5.1% versus 15.1%; P = 0.01). However,
mortality was very high in the control group, even higher than
in the control group of patients who had not been treated
with reperfusion (11.5%). Moreover, the Polish GIK (Pol-GIK)
trial [11], which was published 1 year later, could not confirm
the results of the ECLA pilot trial. In a group of 954 patients,
the mortality of 8.9% in the GIK group was even significantly
higher than that in the control group (4.8%; P = 0.01).
Mortality due to a cardiovascular incident was not
significantly different, and as such the cause of the difference
remained obscure.
The guidelines of the American College of Cardiology/
American Heart Association state that GIK in the treatment of
acute myocardial infarction is very promising, but that it will
take a large randomized study to determine its effectiveness
once and for all [12].
Recently, the Glucose–Insulin–Potassium Study (GIPS) [13]
reached its conclusion. In that study 940 patients were
randomly assigned to primary coronary angioplasty with GIK
(glucose 20% with 80 mmol potassium at a rate of 3 ml/kg
body weight/hour and 50 IU insulin in 50 ml water
administered according to serum glucose concentrations) or
to angioplasty without GIK. Although the mortality reduction
in the overall population did not reach significance, the
results showed that in 856 patients without signs of heart
failure (i.e. Killip class I) the mortality reduction was 3.0%
(P = 0.01).
Conclusion
It is to be expected that in the future the role of GIK, with or
without meticulous glucose regulation, will be established in
the treatment of various conditions [14]. At present clinical
studies only support its effectiveness in patients admitted to
a surgical intensive care unit and treated with meticulous
glucose regulation combined with nutrition, and in patients
with diabetes mellitus and acute myocardial infarction who
are treated with an insulin–glucose infusion and intensive
insulin therapy for at least 3 months. New clinical studies will
show whether experimentally obtained results, such as the
effect of insulin on immune function and apoptosis [15], can
effectively be translated into routine practice, particularly in
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